Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):619–624. doi: 10.1128/aac.37.4.619

Antimicrobial strategies in the care of organ transplant recipients.

R H Rubin 1, N E Tolkoff-Rubin 1
PMCID: PMC187724  PMID: 8494357

Abstract

Since the early days of transplantation, infection has been a major consequence of antirejection immunosuppressive therapy. Increasingly effective prophylactic and preemptive strategies are being developed to prevent the infectious consequences of immunosuppressive therapy. Although the data base is incomplete and there remains a compelling need for well-designed, randomized, comparative trials, the potential for controlling life-threatening viral, bacterial, fungal, and protozoal infections exists. The cornerstone of this effort is the recognition that effective immunosuppressive strategies require an antimicrobial program to make them safe and that such an antimicrobial program needs to be individualized in order to be appropriately matched with the needs of the antirejection program. Thus, escalation and de-escalation of the antimicrobial program should be carried out to match the immunosuppressive program. Infection and rejection remain closely intertwined, linked by the immunosuppressive program that is prescribed.

Full text

PDF
624

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrei G., Snoeck R., Schols D., Goubau P., Desmyter J., De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis. 1991 Dec;10(12):1026–1033. doi: 10.1007/BF01984924. [DOI] [PubMed] [Google Scholar]
  2. Bailey T. C., Trulock E. P., Ettinger N. A., Storch G. A., Cooper J. D., Powderly W. G. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis. 1992 Mar;165(3):548–552. doi: 10.1093/infdis/165.3.548. [DOI] [PubMed] [Google Scholar]
  3. Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
  4. Balfour H. H., Jr Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis Suppl. 1991;80:88–93. [PubMed] [Google Scholar]
  5. Bubak M. E., Porayko M. K., Krom R. A., Wiesner R. H. Complications of liver biopsy in liver transplant patients: increased sepsis associated with choledochojejunostomy. Hepatology. 1991 Dec;14(6):1063–1065. [PubMed] [Google Scholar]
  6. Castaldo P., Stratta R. J., Wood R. P., Markin R. S., Patil K. D., Shaefer M. S., Langnas A. N., Reed E. C., Li S. J., Pillen T. J. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg. 1991 Feb;126(2):149–156. doi: 10.1001/archsurg.1991.01410260033005. [DOI] [PubMed] [Google Scholar]
  7. Chou S. W. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J Infect Dis. 1989 Jul;160(1):16–21. doi: 10.1093/infdis/160.1.16. [DOI] [PubMed] [Google Scholar]
  8. Cooper D. K., Novitzky D., Schlegel V., Muchmore J. S., Cucchiara A., Zuhdi N. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant. 1991 Sep-Oct;10(5 Pt 1):656–663. [PubMed] [Google Scholar]
  9. Cuervas-Mons V., Barrios C., Garrido A., Escartin P., Arcas M., Portero F., Mora N. P., Turrion V. S., Herrera J., Pereira F. Bacterial infections in liver transplant patients under selective decontamination with norfloxacin. Transplant Proc. 1989 Jun;21(3):3558–3558. [PubMed] [Google Scholar]
  10. Drobyski W. R., Knox K. K., Carrigan D. R., Ash R. C. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation. 1991 Jul;52(1):155–157. [PubMed] [Google Scholar]
  11. Dummer J. S., Hardy A., Poorsattar A., Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation. 1983 Sep;36(3):259–267. doi: 10.1097/00007890-198309000-00007. [DOI] [PubMed] [Google Scholar]
  12. Duncan S. R., Cook D. J. Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis. Transplantation. 1991 Nov;52(5):910–913. [PubMed] [Google Scholar]
  13. Dussaix E., Wood C. Cytomegalovirus infection in pediatric liver recipients. A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment. Transplantation. 1989 Aug;48(2):272–274. [PubMed] [Google Scholar]
  14. Emanuel D., Cunningham I., Jules-Elysee K., Brochstein J. A., Kernan N. A., Laver J., Stover D., White D. A., Fels A., Polsky B. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988 Nov 15;109(10):777–782. doi: 10.7326/0003-4819-109-10-777. [DOI] [PubMed] [Google Scholar]
  15. Farrell H. E., Shellam G. R. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol. 1991 Jan;72(Pt 1):149–156. doi: 10.1099/0022-1317-72-1-149. [DOI] [PubMed] [Google Scholar]
  16. Fletcher C. V., Englund J. A., Edelman C. K., Gross C. R., Dunn D. L., Balfour H. H., Jr Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother. 1991 May;35(5):938–943. doi: 10.1128/aac.35.5.938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fox B. C., Sollinger H. W., Belzer F. O., Maki D. G. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990 Sep;89(3):255–274. doi: 10.1016/0002-9343(90)90337-d. [DOI] [PubMed] [Google Scholar]
  18. Goodrich J. M., Mori M., Gleaves C. A., Du Mond C., Cays M., Ebeling D. F., Buhles W. C., DeArmond B., Meyers J. D. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991 Dec 5;325(23):1601–1607. doi: 10.1056/NEJM199112053252303. [DOI] [PubMed] [Google Scholar]
  19. Hakim M., Esmore D., Wallwork J., English T. A., Wreghitt T. Toxoplasmosis in cardiac transplantation. Br Med J (Clin Res Ed) 1986 Apr 26;292(6528):1108–1108. doi: 10.1136/bmj.292.6528.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hardy A. M., Wajszczuk C. P., Suffredini A. F., Hakala T. R., Ho M. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis. 1984 Feb;149(2):143–147. doi: 10.1093/infdis/149.2.143. [DOI] [PubMed] [Google Scholar]
  21. Hibberd P. L., Tolkoff-Rubin N. E., Cosimi A. B., Schooley R. T., Isaacson D., Doran M., Delvecchio A., Delmonico F. L., Auchincloss H., Jr, Rubin R. H. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992 Jan;53(1):68–72. doi: 10.1097/00007890-199201000-00013. [DOI] [PubMed] [Google Scholar]
  22. Higgins R. M., Bloom S. L., Hopkin J. M., Morris P. J. The risks and benefits of low-dose cotrimoxazole prophylaxis for Pneumocystis pneumonia in renal transplantation. Transplantation. 1989 Mar;47(3):558–560. [PubMed] [Google Scholar]
  23. Hofflin J. M., Potasman I., Baldwin J. C., Oyer P. E., Stinson E. B., Remington J. S. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med. 1987 Feb;106(2):209–216. doi: 10.7326/0003-4819-106-2-209. [DOI] [PubMed] [Google Scholar]
  24. Hsia K., Spector D. H., Lawrie J., Spector S. A. Enzymatic amplification of human cytomegalovirus sequences by polymerase chain reaction. J Clin Microbiol. 1989 Aug;27(8):1802–1809. doi: 10.1128/jcm.27.8.1802-1809.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Jacobson M. A., Drew W. L., Feinberg J., O'Donnell J. J., Whitmore P. V., Miner R. D., Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. 1991 Jun;163(6):1348–1351. doi: 10.1093/infdis/163.6.1348. [DOI] [PubMed] [Google Scholar]
  26. Kramer M. R., Stoehr C., Lewiston N. J., Starnes V. A., Theodore J. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long? Transplantation. 1992 Mar;53(3):586–589. doi: 10.1097/00007890-199203000-00019. [DOI] [PubMed] [Google Scholar]
  27. Merigan T. C., Renlund D. G., Keay S., Bristow M. R., Starnes V., O'Connell J. B., Resta S., Dunn D., Gamberg P., Ratkovec R. M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992 Apr 30;326(18):1182–1186. doi: 10.1056/NEJM199204303261803. [DOI] [PubMed] [Google Scholar]
  28. Metselaar H. J., Rothbarth P. H., Brouwer R. M., Wenting G. J., Jeekel J., Weimar W. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation. 1989 Aug;48(2):264–266. doi: 10.1097/00007890-198908000-00016. [DOI] [PubMed] [Google Scholar]
  29. Mora N. P., Klintmalm G., Solomon H., Goldstein R. M., Gonwa T. A., Husberg B. S. Selective amphotericin B prophylaxis in the reduction of fungal infections after liver transplant. Transplant Proc. 1992 Feb;24(1):154–155. [PubMed] [Google Scholar]
  30. Morgan J. S., Schaffner W., Stone W. J. Opportunistic strongyloidiasis in renal transplant recipients. Transplantation. 1986 Nov;42(5):518–524. doi: 10.1097/00007890-198611000-00016. [DOI] [PubMed] [Google Scholar]
  31. Nyberg G., Svalander C., Blohmé I., Persson H. Tubulointerstitial nephritis caused by the antiviral agent foscarnet. Transpl Int. 1989 Dec;2(4):223–227. doi: 10.1007/BF02414539. [DOI] [PubMed] [Google Scholar]
  32. Paya C. V., Hermans P. E., Washington J. A., 2nd, Smith T. F., Anhalt J. P., Wiesner R. H., Krom R. A. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc. 1989 May;64(5):555–564. doi: 10.1016/s0025-6196(12)65561-x. [DOI] [PubMed] [Google Scholar]
  33. Reed E. C., Bowden R. A., Dandliker P. S., Lilleby K. E., Meyers J. D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988 Nov 15;109(10):783–788. doi: 10.7326/0003-4819-109-10-783. [DOI] [PubMed] [Google Scholar]
  34. Ringdén O., Lönnqvist B., Paulin T., Ahlmén J., Klintmalm G., Wahren B., Lernestedt J. O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother. 1986 Mar;17(3):373–387. doi: 10.1093/jac/17.3.373. [DOI] [PubMed] [Google Scholar]
  35. Rondeau E., Farquet C., Fries D., Sraer J. D. Traitement des infections à cytomégalovirus par le ganciclovir chez les transplantés rénaux. Etude clinique et pharmacocinétique. Presse Med. 1991 Nov 27;20(40):2030–2032. [PubMed] [Google Scholar]
  36. Rubin R. H. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S754–S766. doi: 10.1093/clinids/12.supplement_7.s754. [DOI] [PubMed] [Google Scholar]
  37. Rubin R. H., Lynch P., Pasternack M. S., Schoenfeld D., Medearis D. N., Jr Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother. 1989 Nov;33(11):1975–1979. doi: 10.1128/aac.33.11.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rubin R. H. Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991 Apr 11;324(15):1057–1059. doi: 10.1056/NEJM199104113241509. [DOI] [PubMed] [Google Scholar]
  39. Rubin R. H., Tolkoff-Rubin N. E. The impact of infection on the outcome of transplantation. Transplant Proc. 1991 Aug;23(4):2068–2074. [PubMed] [Google Scholar]
  40. Schmidt G. M., Horak D. A., Niland J. C., Duncan S. R., Forman S. J., Zaia J. A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991 Apr 11;324(15):1005–1011. doi: 10.1056/NEJM199104113241501. [DOI] [PubMed] [Google Scholar]
  41. Snydman D. R., Werner B. G., Heinze-Lacey B., Berardi V. P., Tilney N. L., Kirkman R. L., Milford E. L., Cho S. I., Bush H. L., Jr, Levey A. S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987 Oct 22;317(17):1049–1054. doi: 10.1056/NEJM198710223171703. [DOI] [PubMed] [Google Scholar]
  42. Steinmuller D. R., Graneto D., Swift C., Novick A. C., Streem S. B., Cunningham R. J., Hodge E., Bretan P. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation. Transplant Proc. 1989 Feb;21(1 Pt 2):2069–2071. [PubMed] [Google Scholar]
  43. Steinmuller D. R., Novick A. C., Streem S. B., Graneto D., Swift C. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation. 1990 Jan;49(1):68–70. doi: 10.1097/00007890-199001000-00015. [DOI] [PubMed] [Google Scholar]
  44. Stratta R. J., Shaefer M. S., Cushing K. A., Markin R. S., Reed E. C., Langnas A. N., Pillen T. J., Shaw B. W., Jr A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg. 1992 Jan;127(1):55–64. doi: 10.1001/archsurg.1992.01420010065009. [DOI] [PubMed] [Google Scholar]
  45. Sullivan V., Coen D. M. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis. 1991 Oct;164(4):781–784. doi: 10.1093/infdis/164.4.781. [DOI] [PubMed] [Google Scholar]
  46. The T. H., van der Bij W., van den Berg A. P., van der Giessen M., Weits J., Sprenger H. G., van Son W. J. Cytomegalovirus antigenemia. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S734–S744. [PubMed] [Google Scholar]
  47. Tillegård A. Renal transplant wound infection: the value of prophylactic antibiotic treatment. Scand J Urol Nephrol. 1984;18(3):215–221. doi: 10.3109/00365598409180186. [DOI] [PubMed] [Google Scholar]
  48. Tolkoff-Rubin N. E., Cosimi A. B., Russell P. S., Rubin R. H. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis. 1982 Mar-Apr;4(2):614–618. doi: 10.1093/clinids/4.2.614. [DOI] [PubMed] [Google Scholar]
  49. Townsend T. R., Rudolf L. E., Westervelt F. B., Jr, Mandell G. L., Wenzel R. P. Prophylactic antibiotic therapy with cefamandole and tobramycin for patients undergoing renal transplantation. Infect Control. 1980 Mar-Apr;1(2):93–96. doi: 10.1017/s0195941700052619. [DOI] [PubMed] [Google Scholar]
  50. Wajszczuk C. P., Dummer J. S., Ho M., Van Thiel D. H., Starzl T. E., Iwatsuki S., Shaw B., Jr Fungal infections in liver transplant recipients. Transplantation. 1985 Oct;40(4):347–353. doi: 10.1097/00007890-198510000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wiesner R. H., Hermans P. E., Rakela J., Washington J. A., 2nd, Perkins J. D., DiCecco S., Krom R. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation. 1988 Mar;45(3):570–574. doi: 10.1097/00007890-198803000-00014. [DOI] [PubMed] [Google Scholar]
  52. Wiesner R. H. The incidence of gram-negative bacterial and fungal infections in liver transplant patients treated with selective decontamination. Infection. 1990;18 (Suppl 1):S19–S21. doi: 10.1007/BF01644482. [DOI] [PubMed] [Google Scholar]
  53. Wong T., Toupance O., Chanard J. Acyclovir to prevent cytomegalovirus infection after renal transplantation. Ann Intern Med. 1991 Jul 1;115(1):68–68. doi: 10.7326/0003-4819-115-1-68_1. [DOI] [PubMed] [Google Scholar]
  54. van Saene H. K., Stoutenbeek C. P., Gilbertson A. A. Review of available trials of selective decontamination of the digestive tract (SDD). Infection. 1990;18 (Suppl 1):S5–S9. doi: 10.1007/BF01644479. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES